Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines

Matthew J. Vukovich, Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Nagarajan Raju, Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Prudence Kgagudi, MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Nelia P. Manamela, MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Alexandra A. Abu-Shmais, Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kathryn R. Gripenstraw, Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Perry T. Wasdin, Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Xiaoying Shen, Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Bridget Dwyer, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Jumana Akoad, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Rebecca M. Lynch, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
David C. Montefiori, Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Simone I. Richardson, MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Penny L. Moore, MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Ivelin S. Georgiev, Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Document Type

Journal Article

Publication Date

1-23-2024

Journal

Journal of virology

Volume

98

Issue

1

DOI

10.1128/jvi.01478-23

Keywords

HIV-1; LIBRA-seq; guinea pig; immunogen; monoclonal antibodies; vaccine

Abstract

Consistent elicitation of serum antibody responses that neutralize diverse clades of HIV-1 remains a primary goal of HIV-1 vaccine research. Prior work has defined key features of soluble HIV-1 Envelope (Env) immunogen cocktails that influence the neutralization breadth and potency of multivalent vaccine-elicited antibody responses including the number of Env strains in the regimen. We designed immunization groups that consisted of different numbers of SOSIP Env strains to be used in a cocktail immunization strategy: the smallest cocktail (group 2) consisted of a set of two Env strains, which were a subset of the three Env strains that made up group 3, which, in turn, were a subset of the six Env strains that made up group 4. Serum neutralizing titers were modestly broader in guinea pigs that were immunized with a cocktail of three Envs compared to cocktails of two and six, suggesting that multivalent Env immunization could provide a benefit but may be detrimental when the cocktail size is too large. We then adapted the LIBRA-seq platform for antibody discovery to be compatible with guinea pigs, and isolated several tier 2 neutralizing monoclonal antibodies. Three antibodies isolated from two separate guinea pigs were similar in their gene usage and CDR3s, establishing evidence for a guinea pig public clonotype elicited through vaccination. Taken together, this work investigated multivalent HIV-1 Env immunization strategies and provides a novel methodology for screening guinea pig B cell receptor antigen specificity at a high-throughput level using LIBRA-seq.IMPORTANCEMultivalent vaccination with soluble Env immunogens is at the forefront of HIV-1 vaccination strategies but little is known about the influence of the number of Env strains included in vaccine cocktails. Our results suggest that adding more strains is sometimes beneficial but may be detrimental when the number of strains is too high. In addition, we adapted the LIBRA-seq platform to be compatible with guinea pig samples and isolated several tier 2 neutralizing monoclonal antibodies, some of which share V and J gene usage and >70% CDR3 identity, thus establishing the existence of public clonotypes in guinea pigs elicited through vaccination.

Department

Microbiology, Immunology, and Tropical Medicine

Link to Full Text

Share

COinS